Print

Trius Therapeutics (TSRX) Reports Data on Broad-Spectrum Antibiotics at 52nd Annual ICAAC Meeting  
9/13/2012 9:41:10 AM

SAN FRANCISCO, Sept. 12, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, today announced preclinical studies related to a new class of broad-spectrum, gram-negative antibacterial agents that are directed against novel targets Gyrase B (GyrB) and ParE. Trius scientists and research collaborators are presenting the results at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting being held in San Francisco from September 9-12, 2012. Fourteen posters and one podium presentation related to the company's GyrB/ParE preclinical program are being featured, including both in vivo and in vitro studies.
//-->